Short Term, Oral Supplementation with Optimized Curcumin Does Not Impair Performance Improvements Associated with High Intensity Interval Training / Jacob N. Kisiolek, Nikeeta Kheredia, Victoria Flores, Arjun Ramani, Jonathon Lisano, Nora Johnston, Laura K. Stewart
Abstract Curcumin may improve athletic performance through a reduction in inflammation following exercise and improve mental states of well-being. The purpose of this investigation was to explore the effects of a 14 day HIIT intervention and oral supplementation with Longvida ® optimized curcumin on athletic performance, lactate response, and well-being. Sixteen males and twenty females participated in a double-blinded, randomized, placebo-controlled trial to explore the effects of Longvida(R) optimized curcumin (1.0 g/day) and or a placebo (PLA) taken daily during a 14 day HIIT protocol. Participants were randomized into two groups, then evaluated in three groups, curcumin-fast (CURF), curcumin-slow (CURS) and placebo. Curcumin-fast and curcumin-slow were separated by their 16.1 km cycling time trial performance (TT) with CURF and CURS determined by a TT 30 min at the pre intervention time point, respectively. Cycling time-trial performance, blood lactate response, and well-being assessments were determined at pre and post 14 day HIIT intervention time points. Blood lactate was recorded at baseline, 8.01 km, 15.1 km, and 1 min post, and 4 min post of the pre and post intervention TT. Following the internvetion, CONP and CURS experienced with 8.15% and 5.04% improvements in TT performance times, while CURF experienced a 0.57% improvement in TT performance time. No changes were observed with respect to other measures. When curcumin is taken daily in conjunction with 14 days of HIIT on a cycle ergometer, cycling performance in either well trained or more recreationally trained athletes is not impaired. Although the improvements in TT performance were not stasticially significant, they are noteworthy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Journal of dietary supplements - 19(2022), 6, Seite 733-746 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kisiolek, Jacob N. [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Umfang: |
1 Online-Ressource (14 p) |
|---|
| doi: |
10.1080/19390211.2021.1936335 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011131446 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011131446 | ||
| 003 | DE-627 | ||
| 005 | 20230713210846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/19390211.2021.1936335 |2 doi | |
| 035 | |a (DE-627)KFL011131446 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/19390211.2021.1936335 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Kisiolek, Jacob N. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Short Term, Oral Supplementation with Optimized Curcumin Does Not Impair Performance Improvements Associated with High Intensity Interval Training |c Jacob N. Kisiolek, Nikeeta Kheredia, Victoria Flores, Arjun Ramani, Jonathon Lisano, Nora Johnston, Laura K. Stewart |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (14 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Curcumin may improve athletic performance through a reduction in inflammation following exercise and improve mental states of well-being. The purpose of this investigation was to explore the effects of a 14 day HIIT intervention and oral supplementation with Longvida ® optimized curcumin on athletic performance, lactate response, and well-being. Sixteen males and twenty females participated in a double-blinded, randomized, placebo-controlled trial to explore the effects of Longvida(R) optimized curcumin (1.0 g/day) and or a placebo (PLA) taken daily during a 14 day HIIT protocol. Participants were randomized into two groups, then evaluated in three groups, curcumin-fast (CURF), curcumin-slow (CURS) and placebo. Curcumin-fast and curcumin-slow were separated by their 16.1 km cycling time trial performance (TT) with CURF and CURS determined by a TT 30 min at the pre intervention time point, respectively. Cycling time-trial performance, blood lactate response, and well-being assessments were determined at pre and post 14 day HIIT intervention time points. Blood lactate was recorded at baseline, 8.01 km, 15.1 km, and 1 min post, and 4 min post of the pre and post intervention TT. Following the internvetion, CONP and CURS experienced with 8.15% and 5.04% improvements in TT performance times, while CURF experienced a 0.57% improvement in TT performance time. No changes were observed with respect to other measures. When curcumin is taken daily in conjunction with 14 days of HIIT on a cycle ergometer, cycling performance in either well trained or more recreationally trained athletes is not impaired. Although the improvements in TT performance were not stasticially significant, they are noteworthy | ||
| 653 | |a antioxidant | ||
| 653 | |a cytokine | ||
| 653 | |a supplement | ||
| 700 | 1 | |a Kheredia, Nikeeta |e verfasserin |4 aut | |
| 700 | 1 | |a Flores, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Ramani, Arjun |e verfasserin |4 aut | |
| 700 | 1 | |a Lisano, Jonathon |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Nora |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, Laura K. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of dietary supplements |d Abingdon : Taylor & Francis Group, 2008 |g 19(2022), 6, Seite 733-746 |w (DE-627)KFL000006149 |w (DE-600)2470813-6 |w (DE-576)350625468 |x 1939-022X |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2022 |g number:6 |g pages:733-746 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/19390211.2021.1936335 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_05 | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2022 |e 6 |h 733-746 | ||